By Hanna
Greenblott, Senior Consultant
HOUSTON, Sept. 10,
2024 /PRNewswire/ -- Even with incredible scientific
progress, cancer remains the second highest leading cause of death
in the United States (U.S.) and
one of the highest causes of death worldwide. To accelerate and
bolster the great innovations made in therapeutics, diagnostics,
and patient care, the Biden-Harris administration has reignited the
Cancer Moonshot initiative. This program, introduced by then-Vice
President Biden in 2016, is vigorously dedicated to reducing the
fatality of cancer diagnoses, improving the lives of people living
with cancer, and effectively eradicating cancer as we know it
today.
As part of the Cancer Moonshot mission, the Biden-Harris
administration has offered funding opportunities for programs
developing tools for cancer prevention, screening, and other
innovations in cancer therapeutics and diagnostics. The Advanced
Research Projects Agency for Health (ARPA-H) in particular has
published funding opportunity solicitations seeking advancements in
cancer research.
Most notably, ARPA-H unveiled the Platform Optimizing SynBio for
Early Intervention and Detection in Oncology (POSEIDON) initiative.
This program aims to drastically shift the current landscape of
cancer detection through innovative, synthetic biology-based
approaches. The program is designed to develop over-the-counter
Multi-Cancer-Early Detection (MCED) tests that could identify over
30 types of solid tumors at Stage I, thereby increasing the
likelihood of effective treatment and survival. Leveraging the
latest advancements in synthetic biology for sensor and synthetic
reporter designs, POSEIDON aims to create cost-effective,
accessible, and accurate testing methods that could fundamentally
alter cancer care and prevention.
In addition to POSEIDON, several of ARPA-H's Innovative
Solutions Opening (ISO) focus areas highlight the federal
government's interest in cancer-specific programs. For instance,
the Health Science Futures (HSF) ISO is currently seeking
innovative research programs that enable revolutionary advances in
medicine and healthcare. HSF is looking to fund programs that are
developing breakthrough technologies, transformative tools,
platform systems, and other revolutionary technologies. The HSF ISO
specifically highlights a desire to fund cancer programs that fit
the aforementioned areas of interest. Solution summary submissions
are due by March 3, 2025.
Cancer programs can also seek funding through ARPA-H's Proactive
Health Office (PHO). This funding opportunity is designed for
programs that are developing solutions to improve the health span
and health outcomes of Americans prior to the onset of disease
and/or the development of diminished quality of life from illness.
PHO areas of interest include novel prevention, detection, and
prophylactic treatment methods; population-level approaches to
increase the adoption of prevention and wellness behaviors; and
system innovation for the delivery of proactive health outcomes. By
funding programs that feature these areas of interest, PHO seeks to
develop proactive health safety measures that greatly improve the
lives of Americans. PHO is soliciting solution summaries until
March 3, 2025.
The Scalable Solutions Office (SSO) at ARPA-H has put out a call
for solution summaries for projects, including those with a
cancer-driven focus, that endeavor to improve the scalability and
affordability of health care solutions, bridge gaps in underserved
areas, and extend remote access to expertise by developing
location-specific interventions, telemedicine solutions, and mobile
health clinics. SSO encourages submissions that focus on rapid
innovation and the use of partnerships, as well as flexible
distribution networks and streamlined manufacturing processes.
Similarly, solution summaries for this solicitation are due
March 3, 2025.
With Cancer Moonshot, cancer initiatives have taken center stage
and funding opportunities are available for programs that are ready
to rise to the challenge. If your company has considered applying
for ARPA-H funding, your federal funding journey starts here.
EverGlade Consulting is a national consulting firm that helps
organizations win and manage federal awards. We offer
services ranging from Pursuit, Proposal and Post-Award support to
comply with federal regulations at agencies including BARDA, ASPR,
NIH, DTRA, JPEO, DOD, DIU, DOE, and DARPA.
For additional information see the link below.
https://everglade.com/cancer-moonshot-and-the-arpa-h-cancer-funding-landscape/
CONTACT: Info@everglade.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/everglade-consulting-funding-alert-cancer-moonshot-and-the-arpa-h-cancer-funding-landscape-302244208.html
SOURCE EverGlade Consulting